| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 25 | 2024 | 1111 | 6.680 |
Why?
|
| Heart Defects, Congenital | 31 | 2024 | 1813 | 5.700 |
Why?
|
| Norwood Procedures | 6 | 2023 | 100 | 3.290 |
Why?
|
| Hemodynamics | 17 | 2024 | 850 | 3.170 |
Why?
|
| Cardiac Output, Low | 5 | 2020 | 67 | 2.630 |
Why?
|
| Cardiotonic Agents | 5 | 2024 | 138 | 2.360 |
Why?
|
| Oxygen | 12 | 2024 | 555 | 1.820 |
Why?
|
| Milrinone | 3 | 2024 | 30 | 1.810 |
Why?
|
| Hypoplastic Left Heart Syndrome | 6 | 2023 | 252 | 1.810 |
Why?
|
| Child | 57 | 2024 | 24454 | 1.520 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2023 | 73 | 1.490 |
Why?
|
| Infant | 38 | 2024 | 12483 | 1.470 |
Why?
|
| Sodium Bicarbonate | 2 | 2022 | 52 | 1.440 |
Why?
|
| Cardiac Output | 5 | 2024 | 170 | 1.350 |
Why?
|
| Capnography | 2 | 2020 | 13 | 1.270 |
Why?
|
| Length of Stay | 11 | 2024 | 1309 | 1.240 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2022 | 133 | 1.240 |
Why?
|
| Oximetry | 9 | 2024 | 162 | 1.190 |
Why?
|
| Humans | 98 | 2024 | 124778 | 1.190 |
Why?
|
| Peritoneal Dialysis | 2 | 2020 | 119 | 1.150 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 632 | 1.150 |
Why?
|
| Critical Care | 7 | 2023 | 652 | 1.130 |
Why?
|
| Bland White Garland Syndrome | 2 | 2024 | 2 | 1.090 |
Why?
|
| Nicardipine | 2 | 2024 | 18 | 1.090 |
Why?
|
| Retrospective Studies | 39 | 2024 | 16298 | 1.080 |
Why?
|
| Hospitalization | 11 | 2023 | 1781 | 1.080 |
Why?
|
| Nitroprusside | 2 | 2024 | 46 | 1.080 |
Why?
|
| Cardiopulmonary Bypass | 6 | 2021 | 349 | 1.080 |
Why?
|
| Coronavirus Infections | 3 | 2021 | 359 | 1.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 1.070 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 375 | 1.070 |
Why?
|
| Infant, Newborn | 23 | 2024 | 8181 | 1.030 |
Why?
|
| Intensive Care Units, Pediatric | 9 | 2024 | 480 | 1.030 |
Why?
|
| Hypertension, Pulmonary | 3 | 2020 | 435 | 1.020 |
Why?
|
| Postoperative Care | 6 | 2020 | 296 | 1.000 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 224 | 0.990 |
Why?
|
| Postoperative Period | 7 | 2022 | 334 | 0.980 |
Why?
|
| Postoperative Complications | 8 | 2024 | 3068 | 0.950 |
Why?
|
| Heart Failure, Diastolic | 1 | 2024 | 11 | 0.940 |
Why?
|
| Pulmonary Artery | 5 | 2024 | 440 | 0.940 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1091 | 0.930 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 172 | 0.920 |
Why?
|
| Hemodynamic Monitoring | 1 | 2024 | 12 | 0.920 |
Why?
|
| Dobutamine | 1 | 2024 | 55 | 0.920 |
Why?
|
| Diuretics | 3 | 2024 | 171 | 0.920 |
Why?
|
| Splanchnic Circulation | 1 | 2024 | 53 | 0.920 |
Why?
|
| Heart Failure, Systolic | 1 | 2024 | 32 | 0.900 |
Why?
|
| Hepatic Veins | 1 | 2023 | 22 | 0.880 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2023 | 628 | 0.880 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 39 | 0.860 |
Why?
|
| Epinephrine | 1 | 2024 | 178 | 0.860 |
Why?
|
| Inpatients | 4 | 2023 | 499 | 0.850 |
Why?
|
| Tetralogy of Fallot | 2 | 2023 | 162 | 0.840 |
Why?
|
| Child, Preschool | 20 | 2024 | 14050 | 0.830 |
Why?
|
| Blood Pressure | 8 | 2024 | 1348 | 0.830 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 136 | 0.810 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 723 | 0.790 |
Why?
|
| Lymphocytes | 3 | 2023 | 407 | 0.790 |
Why?
|
| Neutrophils | 3 | 2023 | 379 | 0.760 |
Why?
|
| Pacemaker, Artificial | 1 | 2024 | 176 | 0.750 |
Why?
|
| Pandemics | 5 | 2021 | 1105 | 0.750 |
Why?
|
| Computer Simulation | 1 | 2024 | 645 | 0.750 |
Why?
|
| Treatment Outcome | 20 | 2024 | 12333 | 0.750 |
Why?
|
| Lung | 2 | 2020 | 1491 | 0.730 |
Why?
|
| Pulmonary Surfactants | 1 | 2021 | 43 | 0.730 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 44 | 0.730 |
Why?
|
| Chylothorax | 1 | 2021 | 27 | 0.710 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 79 | 0.700 |
Why?
|
| Vascular Resistance | 3 | 2022 | 186 | 0.700 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 232 | 0.680 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2021 | 146 | 0.670 |
Why?
|
| Critical Illness | 3 | 2020 | 600 | 0.670 |
Why?
|
| Heart Arrest | 2 | 2021 | 351 | 0.670 |
Why?
|
| Fontan Procedure | 4 | 2024 | 184 | 0.660 |
Why?
|
| Drug Utilization | 2 | 2019 | 162 | 0.660 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 489 | 0.660 |
Why?
|
| Acidosis | 1 | 2020 | 94 | 0.640 |
Why?
|
| Triiodothyronine | 1 | 2019 | 64 | 0.640 |
Why?
|
| Vasodilator Agents | 2 | 2024 | 205 | 0.640 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 316 | 0.630 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 241 | 0.630 |
Why?
|
| Pulmonary Atresia | 3 | 2023 | 46 | 0.590 |
Why?
|
| Hypothyroidism | 1 | 2019 | 93 | 0.590 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 153 | 0.580 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2018 | 122 | 0.580 |
Why?
|
| Clinical Deterioration | 1 | 2017 | 11 | 0.580 |
Why?
|
| Multiple Organ Failure | 2 | 2023 | 141 | 0.560 |
Why?
|
| Hospital Mortality | 5 | 2024 | 1027 | 0.560 |
Why?
|
| Nitric Oxide | 2 | 2020 | 446 | 0.560 |
Why?
|
| Hospital Rapid Response Team | 1 | 2017 | 36 | 0.550 |
Why?
|
| Spectroscopy, Near-Infrared | 5 | 2024 | 135 | 0.550 |
Why?
|
| Cause of Death | 1 | 2019 | 472 | 0.540 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 196 | 0.540 |
Why?
|
| Heart Failure | 2 | 2021 | 2301 | 0.520 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2020 | 278 | 0.510 |
Why?
|
| Anesthesia | 1 | 2018 | 211 | 0.500 |
Why?
|
| Male | 28 | 2024 | 61267 | 0.490 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2015 | 19 | 0.490 |
Why?
|
| Scimitar Syndrome | 1 | 2016 | 52 | 0.480 |
Why?
|
| Female | 29 | 2024 | 66534 | 0.480 |
Why?
|
| Ketamine | 1 | 2018 | 215 | 0.470 |
Why?
|
| Heart | 3 | 2023 | 723 | 0.470 |
Why?
|
| Aortic Coarctation | 1 | 2016 | 108 | 0.470 |
Why?
|
| Hypotension | 3 | 2022 | 181 | 0.460 |
Why?
|
| Echocardiography | 5 | 2023 | 1052 | 0.450 |
Why?
|
| Pulmonary Veins | 1 | 2016 | 161 | 0.450 |
Why?
|
| Vena Cava, Superior | 2 | 2021 | 56 | 0.440 |
Why?
|
| Adolescent | 11 | 2024 | 19327 | 0.440 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 255 | 0.420 |
Why?
|
| Vena Cava, Inferior | 2 | 2024 | 103 | 0.420 |
Why?
|
| Lactates | 2 | 2022 | 93 | 0.400 |
Why?
|
| Ventricular Septum | 2 | 2022 | 16 | 0.400 |
Why?
|
| Databases, Factual | 3 | 2024 | 1180 | 0.400 |
Why?
|
| Intensive Care Units | 5 | 2022 | 485 | 0.400 |
Why?
|
| Risk Factors | 10 | 2023 | 10271 | 0.400 |
Why?
|
| Gases | 2 | 2022 | 16 | 0.390 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 174 | 0.390 |
Why?
|
| Leukocyte Count | 3 | 2021 | 250 | 0.380 |
Why?
|
| Aneurysm | 1 | 2012 | 91 | 0.380 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 314 | 0.380 |
Why?
|
| Disease Management | 1 | 2015 | 521 | 0.370 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 3448 | 0.370 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 528 | 0.370 |
Why?
|
| Hypertension | 2 | 2020 | 1314 | 0.360 |
Why?
|
| C-Reactive Protein | 3 | 2021 | 427 | 0.340 |
Why?
|
| Heart Ventricles | 4 | 2023 | 767 | 0.320 |
Why?
|
| Preoperative Period | 2 | 2020 | 88 | 0.320 |
Why?
|
| Biomarkers | 3 | 2023 | 3063 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 1108 | 0.290 |
Why?
|
| Bayes Theorem | 3 | 2024 | 283 | 0.290 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5153 | 0.280 |
Why?
|
| Sepsis | 2 | 2022 | 479 | 0.270 |
Why?
|
| Vasopressins | 3 | 2021 | 43 | 0.270 |
Why?
|
| Prospective Studies | 5 | 2021 | 6136 | 0.270 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 963 | 0.270 |
Why?
|
| Lactic Acid | 2 | 2024 | 153 | 0.270 |
Why?
|
| Cardiology | 2 | 2022 | 502 | 0.260 |
Why?
|
| Age Factors | 4 | 2021 | 2817 | 0.260 |
Why?
|
| Heart Valve Diseases | 2 | 2019 | 171 | 0.250 |
Why?
|
| Respiration, Artificial | 4 | 2024 | 462 | 0.250 |
Why?
|
| Carbon Dioxide | 3 | 2022 | 274 | 0.240 |
Why?
|
| Stroke | 2 | 2023 | 986 | 0.240 |
Why?
|
| Stroke Volume | 2 | 2024 | 481 | 0.230 |
Why?
|
| Ultrasonography | 3 | 2023 | 930 | 0.230 |
Why?
|
| Norepinephrine | 1 | 2024 | 176 | 0.230 |
Why?
|
| Ultrasonography, Doppler | 1 | 2024 | 193 | 0.210 |
Why?
|
| Time Factors | 5 | 2020 | 6308 | 0.210 |
Why?
|
| Blood Gas Analysis | 2 | 2021 | 83 | 0.210 |
Why?
|
| Tidal Volume | 2 | 2020 | 39 | 0.210 |
Why?
|
| United States | 4 | 2024 | 10883 | 0.210 |
Why?
|
| Steroids | 1 | 2024 | 203 | 0.210 |
Why?
|
| Dopamine | 1 | 2024 | 286 | 0.200 |
Why?
|
| Competency-Based Education | 1 | 2023 | 69 | 0.200 |
Why?
|
| Administration, Inhalation | 2 | 2020 | 180 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2023 | 106 | 0.200 |
Why?
|
| Comorbidity | 2 | 2024 | 1531 | 0.200 |
Why?
|
| Bicarbonates | 1 | 2022 | 98 | 0.200 |
Why?
|
| Airway Extubation | 1 | 2022 | 67 | 0.190 |
Why?
|
| Infusions, Intravenous | 2 | 2020 | 549 | 0.190 |
Why?
|
| Coronary Stenosis | 1 | 2022 | 73 | 0.190 |
Why?
|
| Tracheostomy | 1 | 2024 | 193 | 0.190 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 193 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2022 | 126 | 0.190 |
Why?
|
| Surface-Active Agents | 1 | 2021 | 33 | 0.190 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2021 | 24 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3287 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1894 | 0.180 |
Why?
|
| Thoracic Duct | 1 | 2021 | 6 | 0.180 |
Why?
|
| Dialysis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Pleurodesis | 1 | 2021 | 16 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 410 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2021 | 3434 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 1163 | 0.180 |
Why?
|
| Ligation | 1 | 2021 | 135 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 141 | 0.180 |
Why?
|
| Japan | 1 | 2020 | 133 | 0.180 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 135 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 129 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2023 | 190 | 0.170 |
Why?
|
| Antithrombins | 1 | 2020 | 56 | 0.170 |
Why?
|
| Malnutrition | 1 | 2023 | 204 | 0.170 |
Why?
|
| Interactive Ventilatory Support | 1 | 2019 | 1 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2022 | 279 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2021 | 243 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 426 | 0.160 |
Why?
|
| Prognosis | 2 | 2020 | 4607 | 0.160 |
Why?
|
| Heart Septal Defects | 1 | 2019 | 40 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 157 | 0.160 |
Why?
|
| Noonan Syndrome | 1 | 2019 | 30 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 1351 | 0.160 |
Why?
|
| Pneumonia | 1 | 2022 | 326 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 182 | 0.150 |
Why?
|
| Anesthetics, Dissociative | 1 | 2018 | 20 | 0.150 |
Why?
|
| Palliative Care | 1 | 2022 | 429 | 0.150 |
Why?
|
| Heterotaxy Syndrome | 1 | 2019 | 61 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2023 | 374 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2018 | 91 | 0.150 |
Why?
|
| Patient Admission | 1 | 2019 | 187 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 435 | 0.150 |
Why?
|
| Thyroxine | 1 | 2018 | 69 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 196 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2018 | 219 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 80 | 0.140 |
Why?
|
| Ventricular Dysfunction | 1 | 2016 | 25 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 444 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2017 | 181 | 0.140 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 28 | 0.130 |
Why?
|
| Parents | 1 | 2023 | 1029 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 140 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 768 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2023 | 862 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2017 | 286 | 0.130 |
Why?
|
| Reoperation | 1 | 2019 | 833 | 0.130 |
Why?
|
| Ventricular Function | 1 | 2016 | 91 | 0.130 |
Why?
|
| ROC Curve | 3 | 2023 | 565 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 803 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2018 | 384 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1028 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2019 | 1495 | 0.120 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 114 | 0.120 |
Why?
|
| Resuscitation | 1 | 2017 | 246 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 161 | 0.120 |
Why?
|
| Body Weight | 1 | 2019 | 1005 | 0.120 |
Why?
|
| Kidney | 1 | 2021 | 1354 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2018 | 477 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1627 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1245 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1428 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2015 | 428 | 0.110 |
Why?
|
| Incidence | 1 | 2021 | 3144 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1052 | 0.100 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 222 | 0.100 |
Why?
|
| Registries | 1 | 2019 | 1422 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 672 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 276 | 0.090 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 631 | 0.090 |
Why?
|
| Adult | 3 | 2023 | 29458 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 439 | 0.080 |
Why?
|
| Heart Rate | 2 | 2023 | 593 | 0.080 |
Why?
|
| Middle Aged | 3 | 2023 | 26701 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2090 | 0.070 |
Why?
|
| Mediastinum | 1 | 2023 | 41 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2023 | 204 | 0.050 |
Why?
|
| Sample Size | 1 | 2022 | 86 | 0.050 |
Why?
|
| Central Venous Pressure | 1 | 2022 | 25 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 177 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 143 | 0.050 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2023 | 77 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 88 | 0.050 |
Why?
|
| Phentolamine | 1 | 2021 | 20 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2021 | 22 | 0.050 |
Why?
|
| Calcitonin | 1 | 2021 | 31 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 365 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 35 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2021 | 30 | 0.050 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2021 | 87 | 0.040 |
Why?
|
| Seasons | 1 | 2022 | 311 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2021 | 153 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 117 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 245 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2023 | 313 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1401 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2021 | 303 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 279 | 0.040 |
Why?
|
| Hypoxia | 1 | 2021 | 248 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7171 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2020 | 102 | 0.040 |
Why?
|
| Wisconsin | 1 | 2019 | 19 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2019 | 36 | 0.040 |
Why?
|
| Arginine | 1 | 2021 | 330 | 0.040 |
Why?
|
| Respiration | 1 | 2019 | 120 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 158 | 0.040 |
Why?
|
| Heparin | 1 | 2020 | 228 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 198 | 0.040 |
Why?
|
| Diaphragm | 1 | 2019 | 98 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1810 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2023 | 2142 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 431 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2019 | 198 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2879 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 834 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2020 | 590 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 19679 | 0.020 |
Why?
|